Food and Beverage Recalls
Dreyer’s Grand Ice Cream, Inc. recalls Haagen-Dazs Ice Cream Bars
November 3, 2025, Dreyer’s Grand Ice Cream, Inc. is voluntarily recalling a limited number of its Häagen-Dazs Chocolate Dark Chocolate Mini Bars that may contain undeclared wheat. Those with an allergy or severe sensitivity to wheat run the risk of serious or life-threatening allergic reaction if they consume these products.
The affected product is Häagen-Dazs Chocolate Dark Chocolate Mini Bars in the 6-count package with batch code LLA519501 and a Best By date of January 31, 2027.
The affected product was shipped to two retail customers, Kroger and Giant Eagle, in the following states:
- Kroger: (AL, AK, AZ, AR, CA, CO, GA, ID, IL, IN, KS, KY, MI, MS, MO, MT, NE, NV, NM, OH, OR, SC, TN, UT, VA, WA, WV, WI, WY)
- Giant Eagle: (IN, MD, OH, PA, WV)
Batch codes can be identified on the product packaging. Please use the reference images below and look for the batch code LLA519501 under “Best By 31 JAN 2027.”
No other Häagen-Dazs products or other batches of Häagen-Dazs Chocolate Dark Chocolate Mini Bars are affected by this recall.
First and Last Bakery LLC recalls First & Last Marinara Sauce, Puttanesca Sauce, and Meat Flavored Pasta Sauce
First and Last Bakery, LLC of Hartford, CT, is recalling the following products due to a possible health risk identified by the Connecticut Department of Consumer Protection.
- First and Last Original Marinara Sauce, Tomato & Basil
- First and Last Original Traditional Pasta Sauce, Meat Flavored
- First and Last Original Puttanesca Sauce, Mildly Hot & Spicy
The products were distributed in Connecticut and Massachusetts through Big Y and Stop & Shop retail stores, starting on September 22, 2025, and continuing through 09/22/2025
Sales and production of the sauce have been suspended to ensure full compliance with all regulatory requirements.
No illnesses have been reported to date.
Moonlight Companies recalls Moonlight/Kroger Yellow and white peaches
October 29, 2025 – Moonlight Companies is voluntarily recalling California-grown conventional yellow and white peaches because they have the potential to be contaminated with Listeria monocytogenes, an organism that can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Although healthy individuals may suffer only short-term symptoms such as high fever, severe headache, stiffness, nausea, abdominal pain, and diarrhea. Listeria infection can cause miscarriages and stillbirths among pregnant women.
The recalled peaches were sold at retail stores nationwide between September 16, 2025 and October 29, 2025. The peaches were either sold as individual pieces of fruit bearing PLU stickers or as multi-packs. This recall does not include packages or PLU stickers with the words “Washington” and/or “Organic.” The recalled products are listed in the following summary table and images are below.
New Hoque & Sons Inc. recalls Hoque Dry Ghoinnya Fish
New Hoque & Sons Inc Issues Alert on Uneviscerated “Dry Ghoinnya Fish”
New Hoque & Sons Inc. of Maspeth, NY, is recalling its packages of “Dry Ghoinnya Fish” because the product was found to be uneviscerated.
The recalled “Dry Ghoinnya Fish” were distributed nationwide in retail stores. The product comes in a 10-12 pound, clear plastic package marked with an expiration date of 5/19/25 stamped on the bottom. The product UPC code is 908172635412.
The recall was initiated after routine sampling by New York State Department of Agriculture and Markets Food Inspectors and subsequent analysis by Food Laboratory staff revealed the product was not properly eviscerated prior to processing.
Supreme Produce recalls Supreme Produce Peach Salsa
Supreme Produce LLC Voluntarily Recalls Moonlight Peaches Because of Possible Health Risk
Summary of Recall: Supreme LLC. (dba Supreme Produce) is notifying customers of a voluntary recall initiated by its supplier, Moonlight Companies, Moonlight Companies on white and yellow flesh peaches, due to potential contamination with Listeria monocytogenes. The recall affects only the items listed below. Impacted products are no longer available for sale but, customer should look in their refrigerators.
The product is being recalled due to peaches purchased from our retailer have the potential to be contaminated with Listeria monocytogenes, an organism which can cause serious and sometimes fatal infections in young children, frail or older adults, and others with weakened immune systems. Although healthy individuals may suffer only short-term symptoms such as high fever, severe headache, stiffness, nausea, abdominal pain and diarrhea, Listeria infection can cause miscarriages and stillbirths among pregnant women.
Recalled produce was distributed in Kroger retail stores under the Supreme Produce brand within locations located in the following states: IL, CO, GA, WA, IN, MS, TN, AR, OR, MI.
Vanguard Enterprises, LLC. DBA Bedrock MFG recalls Monarch Premium Bali Gold, Red Bali, Green Maeng Da, and White Elephant Kratom powder
October 28, 2025, Vanguard Enterprises, LLC. DBA Bedrock MFG of Boise, Idaho is recalling Monarch Premium Kratom brand Bali Gold, Red Bali, Green Maeng Da, and White Elephant powder because product has the potential to be contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Healthy persons infected with Salmonella often experience fever, diarrhea (which may be bloody), nausea, vomiting and abdominal pain. In rare circumstances, infection with Salmonella can result in the organism getting into the bloodstream and producing more severe illnesses such as arterial infections (i.e., infected aneurysms), endocarditis and arthritis.
The affected Monarch Premium Kratom brand Bali Gold, Red Bali, Green Maeng Da, and White Elephant powder were distributed nationwide in retail stores and through mail orders via the company website https://bedrockbotanicals.com between April 2023 to September 2023.
These kratom powder products are not sold in Alabama, Arkansas, Indiana, Rhode Island, and Wisconsin.
Medical Device and Drug Recalls
Hintermann Series H3 Total Ankle Replacement Has a Higher-Than-Expected Risk of Device Failure: FDA Safety Communication
Post-approval Study Data Update: October 31, 2025
The FDA is providing an update on post-approval study data for the Hintermann Series H3 Total Ankle Replacement (TAR) system.
As provided by the manufacturer in the final post-approval study (PAS) report for the long-term follow-up of patients who were enrolled in the premarket clinical studies, the estimated rate of additional surgery associated with the implanted device to remove or revise metal components is 14.9% at 10 years, compared to the rate at 5 years which was 6.5%. When additional surgery to remove or revise all components (polyethylene [plastic] components as well as metal components) is included, the estimated rate is 31.8% at 10 years, compared to the rate at 5 years which was 19.2%. These rates are based on a statistical calculation of the probability of device component removal or revision using the available time to additional surgery data of patients enrolled in the study. The final data summary for the post-approval study results can be found on the FDA post-approval study webpage.
At this time, the FDA recommendations provided below have not changed. The FDA continues to work with the manufacturer to evaluate all available information about the performance of Hintermann Series H3 TAR systems and the risk of device failure. In addition, the FDA will continue to work with the manufacturer to ensure that patients and providers are aware of the PAS data on the long-term risk of device failure. We will continue to keep the public informed if significant new information becomes available.
Olympus Corporation recalls Olympus Bronchofiberscopes and bronchovideoscopes
Olympus Issues Voluntary Labeling Update for Bronchoscopes Used with Laser Therapy Equipment
CENTER VALLEY, Pa., (October 31, 2025) – Olympus Corporation has announced a voluntary, global medical device corrective action to provide further clarification on the safe and effective use of bronchoscopes with laser therapy, argon plasma coagulation or high-frequency cauterization equipment during therapeutic procedures within the tracheobronchial tree.
This corrective action supersedes the previous related communication in 2023 to address adverse event complaints of endobronchial combustion involving therapeutic instruments with Olympus bronchoscopes, which included one death.
Since the Field Corrective Action in 2023, Olympus conducted additional assessment on the use of bronchoscopes with laser therapy, argon plasma coagulation, and high-frequency cauterization equipment. Through these investigations of clinical conditions, Olympus determined that additional updates to the instructions for use are necessary. Since 2023, Olympus has received reports of four additional incidents involving serious injury, including one from the U.S.
Otsuka ICU Medical LLC recalls ICU Medical 20 mEq Potassium Chloride Injection
FOR IMMEDIATE RELEASE – October 31, 2025 AUSTIN, TX – Otsuka ICU Medical LLC is issuing a voluntary recall to the user level, for a MISLABELLED lot of POTASSIUM CHLORIDE Inj. 20 mEq, NDC 0990-7077-14. The OVERWRAP label of lot 1030613, Expiration Date: 09-30-2026 may incorrectly identify the product as POTASSIUM CHLORIDE Inj. 10 mEq with NDC 0990-7074-26. Otsuka ICU Medical LLC has identified this discrepancy due to a manufacturing issue. The dosage is correctly printed on the labeling affixed to the product bag which is not visible when the 10 mEq OVERWRAP is in place. This notification details the issue and the required steps for you to perform.
If the incorrect dosage on the 10 mEq overwrap is used instead of the correct 20mEq dosage printed on the product, an overdose of potassium chloride is possible. Overdose of potassium chloride can lead to hyperkalemia. Hazards of severe hyperkalemia after large intravenous overdoses causes neuromuscular dysfunction including muscle weakness, ascending paralysis, listlessness, vertigo, mental confusion, hypotension, cardiac dysrhythmias, or death from cardiac arrest. Premature infants, patients on chronic parenteral nutrition, patients who have a history of cardiac arrythmias, patients with chronic renal insufficiency, patients who have acute renal failure, patients on potassium-sparing diuretics—all are at risk for adverse and potentially fatal outcomes. Otsuka ICU Medical LLC has not received reports of adverse events associated with this issue to date.
Read Comments